Royalty Pharma Past Earnings Performance
Past criteria checks 3/6
Royalty Pharma's earnings have been declining at an average annual rate of -29%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 3.8% per year. Royalty Pharma's return on equity is 16.7%, and it has net margins of 50.5%.
Key information
-29.0%
Earnings growth rate
-31.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 3.8% |
| Return on equity | 16.7% |
| Net Margin | 50.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Royalty Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,266 | 1,145 | 228 | 2 |
| 30 Jun 24 | 2,238 | 673 | 229 | 52 |
| 31 Mar 24 | 2,239 | 799 | 222 | 52 |
| 31 Dec 23 | 2,355 | 1,135 | 250 | 52 |
| 30 Sep 23 | 2,324 | 184 | 264 | 102 |
| 30 Jun 23 | 2,361 | 255 | 257 | 77 |
| 31 Mar 23 | 2,359 | 332 | 261 | 77 |
| 31 Dec 22 | 2,237 | 43 | 227 | 177 |
| 30 Sep 22 | 2,247 | 507 | 200 | 230 |
| 30 Jun 22 | 2,259 | 466 | 198 | 295 |
| 31 Mar 22 | 2,278 | 602 | 191 | 298 |
| 31 Dec 21 | 2,289 | 620 | 183 | 200 |
| 30 Sep 21 | 2,286 | 783 | 187 | 104 |
| 30 Jun 21 | 2,239 | 972 | 189 | 19 |
| 31 Mar 21 | 2,195 | 493 | 187 | 21 |
| 31 Dec 20 | 2,122 | 495 | 182 | 26 |
| 30 Sep 20 | 2,008 | 1,745 | 155 | 34 |
| 30 Jun 20 | 1,934 | 1,863 | 130 | 52 |
| 31 Mar 20 | 1,880 | 2,052 | 117 | 68 |
| 31 Dec 19 | 1,814 | 2,349 | 103 | 83 |
| 31 Dec 18 | 1,795 | 1,378 | 62 | 393 |
| 31 Dec 17 | 1,598 | 1,210 | 106 | 118 |
Quality Earnings: RPRX N has a large one-off gain of $348.8M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: RPRX N's current net profit margins (50.5%) are higher than last year (7.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RPRX N's earnings have declined by 29% per year over the past 5 years.
Accelerating Growth: RPRX N's earnings growth over the past year (521%) exceeds its 5-year average (-29% per year).
Earnings vs Industry: RPRX N earnings growth over the past year (521%) exceeded the Pharmaceuticals industry 8.5%.
Return on Equity
High ROE: RPRX N's Return on Equity (16.7%) is considered low.